Citations

Showing 10 of 108104 citations.

N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma
Hálfdánarson, Þorvarður R. , Foster, Nathan R. , Kim, George P., Haddock, Michael G. , Dakhil, Shaker R. , Behrens, Robert J. , Halfdanarson, Thorvardur R , Alberts, Steven R.

Mayo Clinic

The Oncologist | February 2, 2022 | Volume: 27 | Issue: 7 | Pages: 534-e546

10.1093/oncolo/oyac002 | PMID 35285484 Get It

Abstract Background This North Central Cancer Treatment Group (NCCTG) N064A (Alliance) phase II trial evaluated upfront chemoradiotherapy incorporating the EGFR inhibitor panitumumab, followed by gemcitabine and panitumumab for unresectable, non-metastatic pancreatic cancer. Methods The treatment consisted of fluoropyrimidine and panitumumab given concurrently with radiotherapy followed by gemcitabine and panitumumab for 3 cycles followed by maintenance panitumumab. The primary endpoint was the 12-month overall survival (OS) rate and secondary endpoints included confirmed response rate (RR), OS, progression-free survival (PFS), and adverse events. Enrollment of 50 patients was planned and the study fully accrued. Results Fifty-two patients were enrolled, but only 51 were treated and included in the analysis. The median age of patients was 65 years and 54.9% were women. Twenty-two patients received at least 1 cycle of systemic therapy following radiotherapy, but 29 patients received chemoradiotherapy only without receiving subsequent chemotherapy after completion of chemoradiotherapy. The overall RR was 5.9% (95% CI: 1.2%-16.2%). The 12-month OS rate was 50% (95% CI: 38%-67%) which fell short of the per-protocol goal for success (51.1%). The median PFS was 7.4 months (95% CI: 4.5-8.6) and the median OS was 12.1 months (95% CI 7.9-15.9). Grade 3 or higher adverse events were reported by 88%. Conclusion The combination of panitumumab, chemotherapy, and external beam radiation therapy was associated with very high rates of grades 3-4 toxicities and survival results did not meet the trial’s goal for success. This regimen is not recommended for further study (ClinicalTrials.gov Identifier NCT00601627).
A Deep Learning Approach for Detecting Liver Cirrhosis from Volatolomic Analysis of Exhaled Breath
Wieczorek, Mikolaj A. , Weston, Alexander D. , Ledenko, Matthew F, Thomas, Jonathan N., Carter, Rickey E. , Carter, Rickey E , Ledenko, Matthew , Patel, Tushar

Mayo Clinic

No container title available | February 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1258834/v1 Get It

Abstract IntroductionLiver disease such as cirrhosis is known to cause changes in the composition of volatile organic compounds (VOC) present in patient breath samples. Previous studies have demonstrated the diagnosis of liver cirrhosis from these breath samples, but studies are limited to a handful of discrete, well-characterized compounds.MethodsWe utilized VOC profiles from breath samples from 46 individuals, 35 with cirrhosis and 11 healthy controls. A deep-neural network was optimized to discriminate between healthy controls and individuals with cirrhosis.ResultsA 1D convolutional neural network (CNN) was accurate in predicting which patients had cirrhosis with an AUC of 0.90 (95% CI: 0.75, 0.99). Shapley Additive Explanations characterized the presence of discrete, observable peaks which were implicated in prediction, and the top peaks (based on the average SHAP profiles on the test dataset) were noted.ConclusionCNNs demonstrate the ability to predict the presence of cirrhosis based on a full volatolomics profile of patient breath samples. SHAP values indicate the presence of discrete, detectable peaks in the VOC signal.
In reply: ‘multiple etiologies explain the association between sarcoidosis and diabetes mellitus’
El‐Qushayri, Amr Ehab , Ghozy, Sherief , Islam, Sheikh Mohammed Shariful , Islam, Sheikh Mohammed Shariful , Ghozy, Sherief

Mayo Clinic

Expert Review of Respiratory Medicine | February 2, 2022 | Volume: 16 | Issue: 3 | Pages: 369-370

10.1080/17476348.2022.2035221 | PMID 35108145 Get It

The Suprasellar Meningioma Patient-Reported Outcome Survey: a disease-specific patient-reported outcome measure for resection of suprasellar meningioma
Khalafallah, Adham M. , Rakovec, Maureen , Burapachaisri, Katemanee , Fung, Shirley , Kozachik, Sharon , Valappil, Benita, Abou‐Al‐Shaar, Hussam , Zenonos, Georgios A. , Gardner, Paul A. , Başkaya, Mustafa K. , Dornbos, David , Roxbury, Christopher R. , Overdevest, Jonathan B. , Lee, Victoria S. , Levy, Joshua M. , Thamboo, Andrew , Schlosser, Rodney J. , London, Nyall R. , Wu, Albert W., Mukherjee, Debraj , Levy, Joshua M , Schlosser, Rodney J , Mukherjee, Debraj , Wang, Eric W , Snyderman, Carl H , Choby, Garret , Kuan, Edward C , Gudis, David A. , Huang, Judy , Bettegowda, Chetan , Rowan, Nicholas R.

Mayo Clinic

Journal of Neurosurgery | February 2, 2022 | Volume: 136 | Issue: 6 | Pages: 1551-1559

10.3171/2021.6.jns21517 | PMID 34874673 Get It

OBJECTIVE Suprasellar meningioma resection via either the transcranial approach (TCA) or the endoscopic endonasal approach (EEA) is an area of controversy and active evaluation. Skull base surgeons increasingly consider patient-reported outcomes (PROs) when choosing an approach. No PRO measure currently exists to assess quality of life for suprasellar meningiomas. METHODS Adult patients undergoing suprasellar meningioma resection between 2013 and 2019 via EEA (n = 14) or TCA (n = 14) underwent semistructured interviews. Transcripts were coded using a grounded theory approach to identify themes as the basis for a PRO measure that includes all uniquely reported symptoms. To assess content validity, 32 patients and 15 surgeons used a Likert scale to rate the relevance of items on the resulting questionnaire and the general Patient-Reported Outcomes Measurement Information System–29 (PROMIS29). The mean scores were calculated for all items and compared for TCA versus EEA patient cohorts by using unpaired t-tests. Items on either questionnaire with mean scores ≥ 2.0 from patients were considered meaningful and were aggregated to form the novel Suprasellar Meningioma Patient-Reported Outcome Survey (SMPRO) instrument. RESULTS Qualitative analyses resulted in 55 candidate items. Relative to patients who underwent the EEA, those who underwent the TCA reported significantly worse future outlook before surgery (p = 0.01), tiredness from medications 2 weeks after surgery (p = 0.001), and word-finding and memory difficulties 3 months after surgery (p = 0.05 and < 0.001, respectively). The items that patients who received a TCA were most concerned about included medication-induced lethargy after surgery (2.9 ± 1.3), blurry vision before surgery (2.7 ± 1.5), and difficulty reading due to blurry vision before surgery (2.7 ± 2.7). Items that patients who received an EEA were most concerned about included blurry vision before surgery (3.5 ± 1.3), difficulty reading due to blurry vision before surgery (2.4 ± 1.3), and problems with smell postsurgery (2.9 ± 1.3). Although surgeons overall overestimated how concerned patients were about questionnaire items (p < 0.0005), the greatest discrepancies between patient and surgeon relevance scores were for blurry vision pre- and postoperatively (p < 0.001 and < 0.001, respectively) and problems with taste postoperatively (p < 0.001). Seventeen meningioma-specific items were considered meaningful, supplementing 8 significant PROMIS29 items to create the novel 25-item SMPRO. CONCLUSIONS The authors developed a disease- and approach-specific measure for suprasellar meningiomas to compare quality of life by operative approach. If demonstrated to be reliable and valid in future studies, this instrument may assist patients and providers in choosing a personalized surgical approach.
Evaluation of a Novel Wellness Curriculum on Medical Student Wellbeing and Engagement Demonstrates a Need for Student-Driven Wellness Programming
Edmonds, Victoria S. , Chatterjee, Krishanu , Girardo, Marlene , Butterfield, Richard , Stonnington, Cynthia M. , Edmonds, Victoria S

Mayo Clinic

Teaching and Learning in Medicine | February 2, 2022 | Volume: 35 | Issue: 1 | Pages: 52-64

10.1080/10401334.2021.2004415 | PMID 35107397 Get It

Poor Evidence That Endometrial Thickness Underperforms in Detecting Endometrial Cancer in Black Women
Patel, Maitray D., Levine, Deborah, Smith-Bindman, Rebecca, Patel, Maitray D., Levine, Deborah, Smith-Bindman, Rebecca

Mayo Clinic

American Journal of Roentgenology | February 2, 2022 | Volume: 218 | Issue: 3 | Pages: 563-563

10.2214/ajr.21.27055 | PMID 35107299 Get It

An off-the-shelf bioadhesive patch for sutureless repair of gastrointestinal defects
Wu, Jingjing , Yuk, Hyunwoo , Sarrafian, Tiffany L. , Griffiths, Leigh G. , Nabzdyk, Christoph S. , Zhao, Xuanhe , Griffiths, Leigh G , Nabzdyk, Christoph , Zhao, Xuanhe , Sarrafian, Tiffany L , Guo, Chuan Fei

Mayo Clinic

Science Translational Medicine | February 2, 2022 | Volume: 14 | Issue: 630 | Pages: No page available

10.1126/scitranslmed.abh2857 | PMID 35108064 Get It

Surgical sealing and repair of injured and resected gastrointestinal (GI) organs are critical requirements for successful treatment and tissue healing. Despite being the standard of care, hand-sewn closure of GI defects using sutures faces limitations and challenges. In this work, we introduce an off-the-shelf bioadhesive GI patch capable of atraumatic, rapid, robust, and sutureless repair of GI defects. The GI patch integrates a nonadhesive top layer and a dry, bioadhesive bottom layer, resulting in a thin, flexible, transparent, and ready-to-use patch with tissue-matching mechanical properties. The rapid, robust, and sutureless sealing capability of the GI patch is systematically characterized using ex vivo porcine GI organ models. In vitro and in vivo rat models are used to evaluate the biocompatibility and degradability of the GI patch in comparison to commercially available tissue adhesives (Coseal and Histoacryl). To validate the GI patch’s efficacy, we demonstrate successful sutureless in vivo sealing and healing of GI defects in rat colon, stomach, and small intestine as well as in porcine colon injury models. The proposed GI patch provides a promising alternative to suture for repair of GI defects and offers potential clinical opportunities for the repair of other organs.
Physician judgement in predicting obstructive coronary artery disease and adverse events in chest pain patients
Fordyce, Christopher B. , Hill, C. Larry , Pellikka, Patricia A. , Hoffmann, Udo , Patel, Manesh R. , Douglas, Pamela S. , Pellikka, Patricia A , Patel, Manesh R , Douglas, Pamela S , Fordyce, Christopher B , Mark, Daniel B. , Alhanti, Brooke

Mayo Clinic

Heart | February 2, 2022 | Volume: 108 | Issue: 11 | Pages: 860-867

10.1136/heartjnl-2021-320275 | PMID 35110385 Get It

Objective To evaluate informal physician judgement versus pretest probability scores in estimating risk in patients with suspected coronary artery disease (CAD). Methods We included 4533 patients from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial. Physicians categorised a priori the pretest probability of obstructive CAD (≥70% or ≥50% left main); Diamond-Forrester (D-F) and European Society of Cardiology (ESC) pretest probability estimates were calculated. Agreement was calculated using the κ statistic; logistic regression evaluated estimates of pretest CAD probability and actual CAD (as determined by CT coronary angiography), and clinical outcomes were modelled using Cox proportional hazard models. Results Physician estimates agreed poorly with D-F (κ 0.16; 95% CI 0.14 to 0.18) and ESC (κ 0.04; 95% CI 0.02 to 0.05). Actual obstructive CAD was significantly more prevalent in both the high-likelihood (OR 3.30; 95% CI 2.30 to 4.74) and the intermediate-likelihood (OR 1.43; 95% CI 1.16 to 1.76) physician-estimated groups versus the low-likelihood group; ESC similarly differentiated between the three groups (OR 9.07; 95% CI 2.87 to 28.70; and OR 3.87; 95% CI 1.22 to 12.28). However, using D-F, only the high-probability group differed (OR 2.49; 95% CI 1.74 to 3.54). Only physician estimates were associated with a higher incidence of adjusted death/myocardial infarction/unstable angina hospitalisation in the high-probability versus low-probability group (HR 2.68; 95% CI 1.52 to 4.74); neither pretest probability score provided prognostic information. Conclusions Compared with D-F and ESC estimates, physician judgement more accurately identified obstructive CAD and worse patient outcomes. Integrating physician judgement may improve risk prediction for patients with stable chest pain. Trial registration number NCT01174550 .
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Peddi, Parvin F., Fasching, Peter A. , Liu, Duan , Quinaux, Emmanuel, Robert, Nicholas J., Valero, Vicente, Falkson, Carla I. , Brufsky, Adam , Cunningham, Julie M. , Weinshilboum, Richard M., Pienkowski, Tadeusz, Eiermann, Wolfgang, Bee, Valerie, Wang, Xiaoyan, Wang, Liewei, Yang, Eric H. , Slamon, Dennis J., Hurvitz, Sara A., Pieńkowski, Tadeusz , Crown, John , Falkson, Carla , Brufsky, Adam M , Cunningham, Julie M , Martin, Miguel , Yang, Eric , Liu, Duan , Peddi, Parvin F., Fasching, Peter A , Quinaux, Emmanuel, Robert, Nicholas J., Valero, Vicente, Weinshilboum, Richard M., Eiermann, Wolfgang, Bee, Valerie, Wang, Xiaoyan, Wang, Liewei, Slamon, Dennis J., Hurvitz, Sara A.

Mayo Clinic

Clinical Cancer Research | February 2, 2022 | Volume: 28 | Issue: 9 | Pages: 1854-1862

10.1158/1078-0432.ccr-21-1762 | PMID 35110416 Get It

Abstract Purpose: Cardiac toxicity is a serious potential complication of HER2-directed therapies and anthracyclines. HER2 codon 655 and SLC28A3 gene polymorphisms have been reported to be associated with cardiac toxicity from anti-HER2 and anthracycline therapy, respectively. Association of the polymorphism at HER2 codon 655 with prognosis has also been reported. Experimental Design: Whole blood samples from patients treated on a randomized adjuvant breast cancer trial (BCIRG-006) that compared chemotherapy with or without trastuzumab plus either anthracycline or nonanthracycline chemotherapy were tested for genetic polymorphisms in HER2 codon 655 and SLC28A3. Genotypes were correlated with cardiac function and disease-free survival (DFS) outcomes. Results: Of 3,222 patients enrolled in BCIRG-006, 662 patient samples were successfully genotyped for the rs1136201 allele in HER2 (codon 655): 424 (64%) were AA, 30 (4.5%) were GG, and 208 (31%) were AG genotype. In addition, 665 patient samples were successfully genotyped for the rs7853758 allele in the SLC28A3 gene: 19 (3%) were AA, 475 (71%) were GG, and 171 (26%) were AG genotype. Follow-up time was 10 years. No correlation between DFS, cardiac event rate, or mean left ventricular ejection fraction (LVEF) and rs1136201 genotype was seen in the trastuzumab-treated or non–trastuzumab-treated patients. Moreover, mean LVEF and cardiac event rates were similar in all rs7853758 genotype groups treated with anthracycline-based therapy. Conclusions: In the largest study to date to evaluate whether two polymorphisms are associated with DFS and/or cardiac toxicity in HER2-positive breast cancer treated with trastuzumab and/or anthracyclines, we observed no correlation.